This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

Disrupted gut–brain dialogue in depression: the roles of omega-3 fatty acids

A disrupted gut–brain dialogue in depression: the roles of omega-3 fatty acids

Pilot data showed that EPA supplementation tended to increase beneficial taxa in the gut microbiota, particularly Bifidobacterium, but the changes were not statistically significant due to the small sample size.

The study is based on the premise that the gut microbiome and its metabolites play a role in maintaining gut health, regulating immune responses, and influencing the central nervous system through the gut–brain axis; that changes in gut microbial composition have been reported in major depressive disorder (MDD); and that omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), may offer a novel mechanistic link by modulating the microbiota. This pilot study was a 12-week randomized, placebo-controlled trial; 24 patients received 1 g of EPA daily (n = 7), 1 g of docosahexaenoic acid (DHA) daily (n = 8), or bean oil as a placebo (n = 9), and stool samples were collected at baseline and after the intervention for microbiome analysis. In the abstract, the sample was described as patients with attention-deficit/hyperactivity disorder (ADHD), whereas the findings were reported in terms of patients with MDD. In patients with MDD, a trend toward an increase in the Bacteroides phylum and a decrease in Firmicutes was observed, but these changes were not statistically significant due to the small sample size. EPA tended to increase Actinobacteria and, in particular, Bifidobacterium, an important beneficial taxon; a trend toward a decrease in proinflammatory bacteria was also reported in the intervention group. According to the authors, these preliminary data suggest that EPA may modulate the gut microbiota in patients with MDD, but the effects remain unclear due to the small sample size, and larger studies are needed to clarify their clinical significance.

Tüm WCP 2026 özetleri